MarketWatch
With Zepbound approved for sleep apnea, Lilly spends up to $7.8 billion for a company with a narcolepsy drug
The company, which is flush with cash from sales of its market-leading GLP-1 franchise, has been an active dealmaker.
M
Source
MarketWatch
Read full article at MarketWatch
Opens original article in a new tab
Advertisement
